Sintilimab shown to have favourable activity and acceptable toxicity in Chinese patients with relapsed or refractory classical Hodgkin lymphoma.
China’s homegrown drug Sintilimab designed for treating relapsed or refractory classic Hodgkin lymphoma has won international recognition, with its clinical trial research published in The Lancet Haematology.
Hodgkin lymphoma is a rare malignant lymphoma that occurs mostly in young people between the ages of 20 and 40. Although the cure rate of early treatment is high, patients have a 20 percent chance of recurrence after their first treatment. Patients with relapsed or refractory classic Hodgkin lymphoma lack effective treatment in China.
Sintilimab, an anti-PD-1 drug, is a kind of checkpoint inhibitor, an emerging anti-cancer therapeutic modality that boosts the immune system to help the body target and kill tumours.
Professor Shi Yuankai from the Cancer Hospital, Chinese Academy of Medical Sciences, led the clinical research, which enrolled 96 patients with relapsed or refractory classic Hodgkin’s lymphoma from 18 hospitals in China.
Results showed that Sintilimab has favourable activity and acceptable toxicity in Chinese patients with relapsed or refractory classical Hodgkin lymphoma, with 80.4 percent of the patients showing an objective response.
Sintilimab was approved for market authorisation by China’s National Medical Products Administration in December 2018.
“The approval will bring more treatment options for cancer patients in China,” Shi said.
It is hope that the drug will potentially improve the outcomes of patients with classical Hodgkin lymphoma worldwide. [APBN]